Dasatab 100 mg (Tablet)

Unit Price: ৳ 400.00 (3 x 10: ৳ 12,000.00)
Strip Price: ৳ 4,000.00

Medicine Details

Category Details
Generic Dasatinib
Company Eskayef pharmaceuticals ltd
Also available as
Dasatab 20 mg tablet

Indications

  • Treatment of Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase
  • Treatment of chronic, accelerated, or myeloid or lymphoid blast phase Ph+ CML with resistance or intolerance to prior therapy
  • Treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) with resistance or intolerance to prior therapy
  • Treatment of pediatric patients 1 year of age and older with Ph+ CML in chronic phase
  • Treatment of newly diagnosed Ph+ ALL in combination with chemotherapy

Pharmacology

  • Inhibition of BCR-ABL, SRC family, c-KIT, EPHA2, and PDGFRβ kinases
  • Predicted binding to multiple conformations of the ABL kinase
  • Activity in leukemic cell lines representing variants of imatinib mesylate-sensitive and resistant disease
  • Inhibition of the growth of CML and ALL cell lines overexpressing BCR-ABL
  • Absorption between 0.5 to 6 hours following oral administration
  • Distribution with apparent volume of 2505 (CV% 93%)
  • Metabolism primarily by CYP3A4
  • Elimination primarily via the feces

Dosage & Administration

  • Recommended starting dosage for chronic phase CML in adults: 100 mg orally once daily
  • Recommended starting dosage for accelerated phase CML, myeloid or lymphoid blast phase CML, or Ph+ ALL in adults: 140 mg orally once daily
  • Specific recommended starting dosages for pediatric patients based on body weight
  • Tablets should not be crushed, cut, or chewed; they should be swallowed whole
  • Can be taken with or without a meal, either in the morning or in the evening

Interaction

  • Coadministration with strong CYP3A4 inhibitors may increase concentrations
  • Coadministration with strong CYP3A4 inducers may decrease concentrations
  • Coadministration with gastric acid reducing agents may decrease concentrations

Contraindications

  • Known hypersensitivity to Dasatinib or any component of the formulation

Side Effects

  • Myelosuppression
  • Bleeding-related events
  • Fluid retention
  • Cardiovascular events
  • Pulmonary arterial hypertension
  • QT prolongation
  • Severe dermatologic reactions
  • Tumor lysis syndrome

Pregnancy & Lactation

  • Can cause fetal harm when administered to a pregnant woman
  • Females of reproductive potential should be advised to avoid pregnancy during treatment
  • Breastfeeding is not recommended during treatment

Precautions & Warnings

  • Severe thrombocytopenia, neutropenia, and anemia
  • Bleeding risk, especially with concomitant medications that inhibit platelet function or anticoagulants
  • Fluid retention
  • Cardiac dysfunction
  • Pulmonary arterial hypertension risk
  • QT prolongation risk
  • Severe mucocutaneous dermatologic reactions
  • Tumor lysis syndrome risk

Overdose Effects

  • Limited experience with overdose in clinical studies
  • Severe myelosuppression and bleeding observed in reported cases
  • Close monitoring and appropriate supportive treatment for patients ingesting more than recommended dosage

Therapeutic Class

  • Targeted Cancer Therapy

Storage Conditions

  • Store below 30°C in a dry place
  • Protect from light
  • Keep out of the reach of children

Related Brands